Stocks Health care ZYME
NASDAQ · Health careZymeworks Inc. (ZYME)
Zymeworks Inc. brought in $266M of revenue over the twelve months to September 30, 2026, up 97.8% from a year earlier. Net income was $43.3M, a net margin of 16.3%. In fiscal 2025 capital spending exceeded operating cash flow by $34.5M. At September 30, 2026 it held $100.5M in cash against $338.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Zymeworks Inc.
- Net worth
- Zymeworks Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $258.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $106M (+38.9% year on year), with a net loss of $81.1M. Over the 12 months to September 30, 2026: revenue $266M, net income $43.3M.
- Cash flow
- In fiscal 2025 operations used $33M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Zymeworks Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Zymeworks Inc. does
Zymeworks Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZYME.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $106M | -$81.1M | -$1.08 | -$34.5M |
| 2024 | $76.3M | -$122.7M | -$1.62 | -$112M |
| 2023 | $76M | -$118.7M | -$1.72 | -$120.8M |
| 2022 | $412.5M | $124.3M | $1.90 | $136M |
| 2022 | $26.7M | -$211.8M | -$4.61 | -$204.9M |
| 2020 | $39M | -$180.6M | -$3.58 | -$155.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ZYME ranks in Health care
Latest SEC filings
What Zymeworks Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Exhibits 8-K/A
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 829% to $256.5M versus the same quarter last year; diluted EPS $2.28 versus -$0.26.
- November 9, 2026
- October 26, 2026
- October 26, 2026Additional proxy material DEFA14A
- October 26, 2026Proxy statement DEF 14A
- October 23, 2026
- October 16, 2026Preliminary proxy statement PRE 14A
- September 23, 2026Acquisition or sale completed8-KZymeworks completed its acquisition of Theravance Biopharma for $17.00 per share in cash plus contingent value rights.
- August 25, 2026
Insider trades
What the people running Zymeworks Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $357.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 9, 2026 | Schayowitz AdamEVP, Head of R&D | Exercised options | 37,037 | - |
| October 9, 2026 | Schayowitz AdamEVP, Head of R&D | Sold | 13,832 | $357.6K |
| July 6, 2026 | Hollywood MarkEVP & Chief Operating Officer | Received as pay | 939 | $20.9K |
| January 12, 2026 | Hollywood MarkEVP & Chief Operating Officer | Exercised options | 17,666 | - |
| January 12, 2026 | Hollywood MarkEVP & Chief Operating Officer | Sold | 6,120 | $138.8K |
| January 12, 2026 | Galbraith KennethChair & CEO, Director | Exercised options | 64,000 | - |
| January 12, 2026 | Galbraith KennethChair & CEO, Director | Sold | 30,424 | $689.8K |
| January 12, 2026 | Moore Paul AndrewChief Scientific Officer | Exercised options | 17,666 | - |
Who owns ZYME
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| EcoR1 Capital, LLC13D, may seek influence with 2 related filers | 30.7% | November 19, 2025 |
| Rubric Capital Management LP13G, passive with 1 related filers | 9.49% | May 15, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 5.4% | April 15, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 5.2% | November 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 203 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | 0 |
| Rubric Capital Management LP | 7,000,000 | 0 |
| BlackRock, Inc. | 4,251,030 | -302,858 |
| Perceptive Advisors LLC | 4,182,953 | +672,875 |
| Bvf Inc | 3,649,142 | -85,000 |
| Assenagon Asset Management S.A. | 2,504,054 | +1,776,068 |
| Morgan Stanley | 2,231,260 | -249,308 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | -126,923 |
| Vanguard Capital Management LLC | 1,558,998 | -146,582 |
| Nextech Invest Ltd. | 1,113,946 | 0 |
| State Street Corp | 1,088,216 | +76,439 |
| Dimensional Fund Advisors LP | 994,955 | -144,180 |
| Citadel Advisors LLC | 914,136 | -235,882 |
| Nomura Asset Management International Inc. | 889,802 | new |
| Fmr LLC | 702,568 | +35,415 |
| Geode Capital Management, LLC | 692,410 | +32,470 |
| Prosight Management, LP | 674,434 | +135,385 |
| Qube Research & Technologies Ltd | 593,590 | +81,653 |
| Vanguard Portfolio Management LLC | 510,032 | +10,157 |
| Redmile Group, LLC | 491,654 | 0 |
Insiders
6 insiders reported holding 459,563 shares in total, about $14.5M at the last price.
| Holder | Shares |
|---|---|
| Galbraith KennethChair & CEO, Director | 226,842 |
| Hollywood MarkEVP & Chief Operating Officer | 133,852 |
| Moore Paul AndrewChief Scientific Officer | 48,497 |
| Smith Jeffrey T LEVP & Chief Medical Officer | 26,708 |
| Schayowitz AdamEVP, Head of R&D | 23,205 |
| Patterson Leone DEVP, Chief Bus & Fin Officer | 459 |
Questions about ZYME
What does Zymeworks Inc. do?
Zymeworks Inc. is a company in the Health care sector, listed on NASDAQ as ZYME. Its shares trade on NASDAQ under the ticker ZYME.
What is Zymeworks Inc.'s net worth?
Zymeworks Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $258.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zymeworks Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $43.3M on revenue of $266M, a net margin of 16.3%.
How much revenue does Zymeworks Inc. make?
Over the twelve months to September 30, 2026 Zymeworks Inc. reported revenue of $266M. That is 97.8% more than a year earlier.
When did Zymeworks Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Zymeworks Inc.'s next earnings report?
Zymeworks Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ZYME with
Follow ZYME
Get an email when Zymeworks Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zymeworks Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.